The Importance of Disease-Free Survival as a Clinical Trial Endpoint: A Qualitative Study Among Canadian Survivors of Lung Cancer | The Patient - Patient-Centered Outcomes Research
Recurrence/progression-free survival and overall survival among... | Download Scientific Diagram
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
Real-World Progression-Free Survival as an Endpoint in Advanced Non-Small-Cell Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Data Derived From Electronic Health Records | medRxiv
Progression-free survival (PFS) curve and overall survival (OS) curve... | Download Scientific Diagram
PPT - Overall Survival and Progression-Free Survival PowerPoint Presentation - ID:4064400
Survival analysis in hematologic malignancies: recommendations for clinicians | Haematologica
Progression-Free Survival: Meaningful or Simply Measurable? | Journal of Clinical Oncology
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting | Radiation Oncology | Full Text
Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials - The Lancet Oncology
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
Progression-free survival (A) and overall survival (B) | Open-i
Overall survival vs disease-free survival and other surrogate endpoints - survival-analysis - Datamethods Discussion Forum
The frequency of assessment of progression in randomized oncology clinical trials - Haslam - 2022 - Cancer Reports - Wiley Online Library
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma | NEJM
Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting | Radiation Oncology | Full Text
![PDF] Outcomes and endpoints in trials of cancer treatment: the past, present, and future. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/226a8780e04804a8a77db2a45c03766c3e65bf27/3-Figure1-1.png "PDF] Outcomes and endpoints in trials of cancer treatment: the past, present, and future. | Semantic Scholar")
PDF] Outcomes and endpoints in trials of cancer treatment: the past, present, and future. | Semantic Scholar
The Arts, Sciences and Medicine: Progression Free Survival (PFS)
Overall vs. Progression-Free Survival, Response Rates: Oncology Terminology 101 (by Oster Oncology) - YouTube
